Table 3.
Incidence of attrition per 100 PYO stratified by different categories among children on antiretroviral therapy at University of Gondar Compressive Specialized Hospital in Northwest Ethiopia, from January 2005 to December 2018 (n = 344).
| Variables | Total (n = 344) | Censored (n = 239) | Attrition (n = 105) | IR of attrition (95% CI) | PPY |
|---|---|---|---|---|---|
| Age (years) | |||||
| <3 | 84 | 59 | 25 | 7.6 (5.1, 11.2) | 329.9 |
| 4–8 | 127 | 93 | 34 | 5.2 (3.7, 7.3) | 654.8 |
| 9–14 | 133 | 87 | 46 | 7.6 (5.7, 10.1) | 605.4 |
| Sex | |||||
| Male | 178 | 126 | 52 | 6.5 (5.0, 8.5) | 800 |
| Female | 166 | 113 | 53 | 6.7 (5.1, 8.8) | 790.1 |
| Residence | |||||
| Rural | 69 | 46 | 23 | 7.7 (5.1, 11.6) | 298.3 |
| Urban | 275 | 193 | 82 | 6.3 (5.1, 7.9) | 1291.8 |
| Parent status | |||||
| Both alive | 236 | 168 | 68 | 6.4 (5.1, 8.2) | 1056.3 |
| Both or either dead | 108 | 71 | 37 | 6.9 (5.0, 9.6) | 533.6 |
| Caregiver of the child | |||||
| Biological family | 321 | 226 | 95 | 6.4 (5.2, 7.8) | 1493.3 |
| Other | 23 | 13 | 10 | 10.3 (5.6, 19.2) | 96.8 |
| Baseline CD4 count | |||||
| Below threshold | 55 | 33 | 22 | 9.2 (6.1, 14.0) | 238.5 |
| above threshold | 289 | 206 | 83 | 6.1 (5.0, 7.6) | 1351.6 |
| Baseline hemoglobin | |||||
| ⩽10 mg/dL | 43 | 10 | 33 | 22.6 (16.1, 31.8) | 146 |
| ⩾−10 mg/dL | 301 | 229 | 72 | 5.0 (4.0, 6.3) | 1444.1 |
| Baseline weight for age | |||||
| <Under weight | 176 | 94 | 82 | 10.9 (8.8, 13.6) | 751.3 |
| Normal | 168 | 145 | 23 | 2.7 (1.8, 4.1) | 828.8 |
| Baseline height for age | |||||
| Stunting | 141 | 93 | 48 | 7.4 (5.6, 9.8) | 649.1 |
| Normal | 203 | 146 | 57 | 6.1 (5.1, 7.9) | 941 |
| Initial regimen given | |||||
| PI-based | 28 | 14 | 14 | 12.1 (7.2, 20.4) | 115.7 |
| NVP/EVZ-based | 316 | 225 | 91 | 6.2 (5.0, 7.6) | 1474.4 |
| Disclosure status | |||||
| Non-disclosed | 176 | 130 | 46 | 5.7 (4.3, 7.6) | 807.3 |
| Disclosed | 168 | 109 | 59 | 7.5 (5.8, 9.7) | 782.8 |
| Duration on ART | |||||
| <12 months | 35 | 9 | 26 | 107 (73, 150) | 24.2 |
| 12 months to 59 months | 161 | 102 | 59 | 13.2 (10.2, 17) | 447.8 |
| 59 months | 148 | 128 | 20 | 1.8 (1.1, 2.7) | 1118.2 |
| Baseline WHO stage | |||||
| Stages 1 and 2 | 255 | 203 | 52 | 4.3 (3.3, 5.6) | 1209.3 |
| Stages 3 and 4 | 89 | 36 | 53 | 13.9 (10.6, 18.2) | 380.8 |
| Presence of TB | |||||
| Yes | 37 | 17 | 20 | 12.1 (7.8, 18.7) | 165.8 |
| No | 307 | 222 | 85 | 6.0 (4.8, 7.4) | 1424.3 |
| OI other than TB | |||||
| Yes | 113 | 76 | 37 | 7.2 (5.2, 9.9) | 516.8 |
| No | 231 | 163 | 68 | 6.3 (4.9, 8.0) | 1073.3 |
| CPT prophylaxis | |||||
| Yes | 301 | 225 | 76 | 5.2 (4.2, 6.5) | 1454 |
| No | 43 | 14 | 29 | 21 (14.9, 30.7) | 136 |
| IPT prophylaxis | |||||
| Yes | 105 | 73 | 32 | 6.9 (4.9, 9.7) | 465.8 |
| No | 239 | 166 | 73 | 6.5 (5.2, 8.2) | 1124.3 |
| Timing of initiation | |||||
| Early (⩽6 months) | 212 | 141 | 71 | 7.3 (5.8, 9.1) | 977.5 |
| Late (>6 months) | 132 | 98 | 34 | 5.6 (3.9, 7.8) | 612.5 |
| Year of initiations | |||||
| ⩽2013 | 215 | 131 | 84 | 7.2 (5.8, 8.9) | 1165.3 |
| ⩾2014 | 129 | 108 | 21 | 4.9 (3.2, 7.8) | 424.8 |
| Baseline functional status <5 years (n = 248) | |||||
| Working | 226 | 160 | 66 | 6.0 (4.7, 7.7) | 1092.3 |
| Bedridden/ambulatory | 22 | 7 | 15 | 16.6 (10.0, 27.5) | 90.3 |
| Baseline developmental status ⩽5 years (n = 96) | |||||
| Appropriate | 85 | 63 | 22 | 6.0 (4.0, 9.1) | 367.8 |
| Delayed/regressed | 11 | 9 | 2 | 5.0 (1.3, 20.0) | 39.7 |
| Regimen change | |||||
| Yes | 78 | 49 | 29 | 8.6 (6.0, 12.4) | 336.3 |
| No | 267 | 190 | 76 | 6.1 (4.8, 7.6) | 1253.8 |
| Treatment failure | |||||
| Yes | 34 | 23 | 11 | 7.3 (4.1, 13.2) | 151.1 |
| No | 309 | 215 | 94 | 6.5 (5.3, 8.0) | 1439 |
| ART adherence | |||||
| Good | 267 | 187 | 80 | 6.4 (5.1, 7.9) | 1266.8 |
| Fair and poor | 77 | 52 | 25 | 7.7 (5.3, 12.0) | 323.3 |
PI: protease inhibitor; NVP: nevirapine; EVZ: efavirenz; ART: antiretroviral therapy; OI: opportunistic infection; TB: tuberculosis; WHO: World Health Organization; CPT: cotrimoxazole prophylactic therapy; IPT: isoniazid prophylactic therapy; CD4: cluster of differentiation 4; PPY: person per year.